| Name | Title | Contact Details |
|---|
Stuart Therapeutics was established in 2017 for the development and commercialization of PolyCol, a versatile therapeutic platform that offers a unique tissue reparative approach to a variety of ophthalmic disease indications.
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.